Malin Corporation plc: Poseida files for potential IPO on the NASDAQ Global Select Market
Dublin-Ireland, 7 January 2019: Malin Corporation plc (ISE:MLC), a company investing in highly innovative life sciences companies, today notes that its investee company Poseida Therapeutics, Inc. (“Poseida”), a clinical-stage biotechnology company based in San Diego, California, has filed a registration statement on Form S-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of shares of Poseida’s common stock. Poseida has applied to list its common stock on The Nasdaq Global Select Market under the symbol “PSTX”. The number of shares of common stock to be offered and the price range for the offering have not yet been determined.
The Registration Statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the Registration Statement becomes effective.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from the SEC’s EDGAR database and contains further information relating to Poseida.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
For further information, please contact:
Jessica Bergin, Director of Investor Relations & External Reporting
Tel: +353 (0)1 901 5700
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Jonathan Birt
Tel: +44 (0)20 3709 5700
Powerscourt (Ireland PR)
Tel: +353 87 236 5973
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O’Reilly
Tel: +353 1 679 6363
About Malin Corporation plc
Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit www.malinplc.com